1. Introduction {#sec1}
===============

Avascular necrosis of the femoral head (ANFH) is a clinical common orthopaedic disease \[[@B1]--[@B3]\] with very high morbidity. It is difficult to cure and is one of the major medical problems that have not yet been overcome \[[@B4], [@B5]\]. Primary osteonecrosis of the femoral head is due to gene or gene mutation of patients. Secondary osteonecrosis of the femoral head could divide into traumatic and nontraumatic osteonecrosis of femoral head \[[@B6]--[@B8]\], in which traumatic osteonecrosis of the femoral head is the avascular necrosis of osteocyte caused by interruption of blood flow in the blood vessels in femoral head, which was due to trauma \[[@B9], [@B10]\]. Its etiology is still unclear. It was demonstrated that long-term and large dosage usage of hormone and drinking are two important factors that cause ANFN \[[@B4], [@B11]\]. In recent years, with the wide use of corticosteroids clinically, the cases with ANFN have also increased greatly \[[@B12], [@B13]\]. However, the pathogenesis of steroid-induced ANFN is still unknown. For developing new methods to prevent and treat ANFN, study on the pathogenesis of steroid-induced ANFN is particularly urgent \[[@B12], [@B14], [@B15]\].

Recent reports have shown that the occurrence of ANFN could be greatly decreased by an early intervention on high-risk crowds of ANFN who use hormones such as steroid and alcohol \[[@B16]\]. However, the composition of the serum is very complex \[[@B17]\]. It contains high-abundance proteins like albumin and immunoglobulins (mainly IgG), as well as low abundance proteins that are secreted by tissue or cells \[[@B18], [@B19]\]. Some of them are key proteins involved in signal transduction and regulation \[[@B20]\]. Tan et al. \[[@B21]\] adopted two-dimensional electrophoresis technology and separated 7 differentially expressed proteins between patients with primary femoral head necrosis and normal subjects from 10 pairs serum samples. They found that four important proteins including tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor type 1 (PAI-1), Crosslaps, and anti-p53 antibody were significantly changed and that all of them can be used as the diagnosis serum markers of nontraumatic femoral head necrosis. Although the pathogenesis of ANFN is still unclear and the relevance of this finding with the further clinical application was not reported, analysis of the differentially expressed proteins in the serum could provide useful information.

Traditional Chinese Medicine (TCM) Yuanshi Shengmai Chenggu Tablet is valid and specialty drug for steroid-induced ANFN treatment. Yuanshi Shengmai Chenggu Tablet has obtained the certificate of new medicine in China and has been applied in clinical \[[@B22]\]. Its active ingredients are mainly flavonoids such as vitexin. By clinical studies, it was demonstrated the application of Yuanshi Shengmai Chenggu Tablet can significantly relieve the patients\' pain and accelerate the absorption of dead bone and formation of new bone, showing a relatively strong osteogenetic activity \[[@B22]\].

Liu et al. \[[@B23]\] extracted proteins in bone tissue from the femur and humerus bone in rat osteonecrosis model with or without Yuanshi Shengmai Chenggu Tablet TCM treatment and performed proteomics research. They reported that anticoagulating proteins heavy chain II B, phospholipid hydroperoxide glutathione peroxidase, and ubiquitin enzymes E2 (MW: 17 kD) are closely associated with steroid-induced bone necrosis, as well as the therapeutic efficacy of TCM.

In this study we aimed to investigate the differentially expressed protein in serum between steroid-induced ANFN patients with or without TCM treatment (Yuanshi Shengmai Chenggu Tablets). For this purpose, the proteomics method isobaric tags for relative and absolute quantification (iTRAQ) with multiple reaction monitoring (MRM) quantification was adopted in this study, so as to reveal the molecular mechanism of TCM treated the SANFN in the molecular level.

2. Material and Methods {#sec2}
=======================

2.1. Participants {#sec2.1}
-----------------

Patients diagnosed as ANFN in the First Affiliated Hospital of Traditional Chinese Medicine University of Guangzhou from February 2014 to February 2015 were included. The ANFN diagnosis was established by referring to standard of adult femoral head necrosis diagnosis expert consensus (2012 edition) and the diagnosis and treatment of avascular necrosis of the expert advice of diagnostic criteria. Patients in active period of ANFN, alcoholics who are simultaneously treated by long-term high dose of glucocorticoids (taken steroid \> 10 mg/d longer than 3 years), or patients with combining chronic disease which needs prolonged treatment were excluded in present study. All participants gave written informed consent before being enrolled in the study (AE-2013012011).

2.2. Specimens and Groups {#sec2.2}
-------------------------

Patients with ANFN who have used long-term and high-dosage of steroid (SANFN) were further treated with TCM Yuanshi Shengmai Chenggu Tablet (6 tablets each time, 3 times per day, total 3 months; prepared by the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China). Serum samples (*n* = 5) from patients with or without TCM were prospectively collected after obtaining written informed consent. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine. Five healthy subjects were collected during the same period who were sex- and age-matched. Thus, the verification population was divided into 3 groups: steroid-induced avascular necrosis of femoral head (SANFH), SANFH-TCM treatment, and healthy controls.

All serum samples were centrifuged at 1250*g* for 5 min and then 13500*g* for 15 min at 4°C within 1 h of collection. All samples were then stored at −80°C until use.

2.3. iTRAQ Analysis of Serum Samples {#sec2.3}
------------------------------------

iTRAQ labeling and mass spectrometry analysis were performed as previously described \[[@B24]\]. Then, six iTRAQ labeled sample polls were generated (steroid-induced avascular necrosis of femoral head, SANFH-TCM treatment, and health controls, each for two subgroups). Briefly, high-abundance serum proteins such as albumin, IgG, and haptoglobin were removed by using the Human 14 Multiple Affinity Removal System (Agilent Technologies, Santa Clara, CA, USA). Then, 50 *μ*g protein of each sample was concentrated and desalted, followed by digestion using trypsin before iTRAQ labeling. Six groups were labeled, including steroid-induced avascular necrosis of femoral head, iTRAQ reagent 113, 116; SANFH-TCM treatment 114, 117; and health controls 115, 118. The six sample groups were mixed, desalted, and dried.

The iTRAQ labeled peptides were separated by Strong Cation Exchange (SCX) chromatography (Bonna-Agela Technologies, Tianjin, China). SCX was carried out on a Polysulfoethyl 4.6 × 100 mm column (5 *μ*m, 200 Å, PolyLC Inc., Maryland, USA). The peptides were eluted at the 45 min gradient from 100% buffer A (10 mM KH~2~PO~4~ pH 3.0, 25% acetonitrile) to 45% buffer B (10 mM KH~2~PO~4~ pH 3.0, 500 mM KCl, 25% acetonitrile) at the flow rate of 800 *μ*L/min on Agilent 1210 LC system. All the fractions were analyzed by MALDI-TOF/TOF 5800 mass spectrometer (AB SCIEX, California, USA). Protein quantification and identification were performed with the Proteome Discoverer (version 1.3, thermos). The default bias correction was used and all quantitative variables were analyzed by the Proteome Discoverer 1.3. Peptide abundances were calculated based on the areas of the monoisotopic peaks. Protein ratios were the average ratios of all quantified peptides. Proteins with quantification *P* value \< 0.05 in at least two pairs (113 : 114, 113 : 115, 114 : 115; 116 : 117, 116 : 118, 117 : 118) and with the ratio \> 1.2 (the average ratio of two repeat experiments) or ratio \< 0.83 were considered as differentially expressed proteins, using a cutoff of 2 times standard deviation \[[@B25]\].

2.4. Bioinformatics Analysis {#sec2.4}
----------------------------

Biomarker candidates were then prioritized using scoring a system based on iTRAQ values from Proteome Discoverer analysis. The cellular component, molecular function, and biological process were analyzed through Gene Ontology (GO) database. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway mapping was performed by KEGG Mapper (<http://www.genome.jp/kegg/mapper.html>), and the enrichment analysis was performed by Blast2GO PRO software (<https://www.blast2go.com/>, version 2.8).

2.5. Validation of Differential Expressed Protein by Multiple Reaction Monitoring (MRM) Quantification {#sec2.5}
------------------------------------------------------------------------------------------------------

To validate the expression of biomarker candidates, MRM quantifications were performed as previously described \[[@B26]\]. Briefly, 30 *μ*g protein of each sample was digested using trypsin before being desalted. Then, desalted peptide mixtures were loaded onto an Acclaim PePmap C18-reversed phase column (100 Ǻ, Thermo Scientific, Massachusetts, USA) and separated with reversed phase C18 column (300 Ǻ, Bonna-Agela Technologies) mounted on a Dionex ultimate 3000 nano-LC system. Peptides were eluted using a gradient of 5--80% (v/v) acetonitrile in 0.1% formic acid over 45 min at a flow rate of 300 nL/min combined with a Q Exactive mass spectrometer (Thermo Scientific, Massachusetts, USA), and then the eluates were directly entered in Q Exactive MS (Thermo Scientific, Massachusetts, USA), setting in positive ion mode and data-dependent manner with full MS scan within 350--2000 *m*/*z*, full scan resolution at 70000, MS/MS scan resolution at 17500, and MS/MS scan with minimum signal threshold 1*E* + 5, isolation width at 2 Da. To evaluate the performance of this mass spectrometry on the iTRAQ labeled samples, two MS/MS acquisition modes and higher collision energy dissociation (HCD) were employed. And to optimize the MS/MS acquisition efficiency of HCD, normalized collision energy (NCE) was systemically examined, stepped 20%. Each MS/MS spectrum was searched against a mascot database (Uniprot_2015_human database, 20194 protein entries) and a decoy database for FDR analysis (programmed in the software). The search parameters were as follows: sample type, iTRAQ 8-plex (Peptide Labeled); cysteine modification by methyl methane-thiosulfonate; digestion, trypsin enzyme; proteins with, at least, two peptides with a high confidence score (\>95%) and a low FDR (estimated local FDR of 5%) were considered positively identified.

2.6. Statistical Analysis {#sec2.6}
-------------------------

All studies to identify biomarkers by iTRAQ/MRM LC-MS/MS were performed on three separate occasions. Statistical analysis was performed using R (version 3.4.2, Bell Laboratories, USA). Analysis of variance (ANOVA) was performed for groups comparison. A *P* value \< 0.05 was considered as statistical significantly.

3. Results {#sec3}
==========

3.1. Populations {#sec3.1}
----------------

A total of 26 patients were included in the present study. Demographic characteristics of present population were summarized in [Table 1](#tab1){ref-type="table"}. All of them were diagnosed as Association Research Circulation Osseous (ARCO) II stage SONFH, and the time windows of being illness were from 6 to 34 months. The mean age was 39.5 years old and 11 (42.3%) of them were males, suggesting that the patients SONFH were younger. Primary cause of 50% of patients was systemic lupus erythematosus, indicating a high risk of long-term high dose of steroid in systemic lupus erythematosus.

3.2. Protein Identification and Differentially Abundant Proteins {#sec3.2}
----------------------------------------------------------------

Serum proteins of steroid-induced ANSF (SANFH) patients, SANFH-TCM treatment patients, and health subjects were screened using iTRAQ. The experiment was repeated twice and detected 399 proteins. Among them, 61 proteins were differentially expressed between SANFH and healthy controls ([Table 2](#tab2){ref-type="table"}), including 35 significantly upregulated proteins (\>1.21-fold, *P* \< 0.05) and 26 significantly downregulated proteins (\<0.83-fold, *P* \< 0.05). The top four upregulated proteins in SANFH compared to healthy controls were serum amyloid A-2 (SAA2), Ig lambda, sodium/potassium-transporting ATPase subunit alpha-3 (ATP1A3), and calcium-binding mitochondrial carrier protein Aralar1 (SLC25A12) with fold change values of 4.57, 2.64, 2.07, and 1.95. The top four downregulated proteins were properdin, keratin type I cytoskeletal 9 (KRT9), apolipoprotein (a) (LPA), and tropomyosin alpha-4 (TPM4) with fold change values of −1.77, −1.57, −1.65, and −1.61, respectively.

A total of 74 proteins were differentially expressed between SANFH-TCM and healthy controls ([Table 3](#tab3){ref-type="table"}), including 45 significantly upregulated proteins (\>1.21-fold, *P* \< 0.05), and 29 significantly downregulated proteins (\<0.83-fold, *P* \< 0.05). The top four upregulated proteins in SANFH-TCM compared to healthy controls were ATP-binding cassette subfamily B member 9 (ABCB9), fibrinogen alpha, fibrinogen gamma, and fibrinogen beta with fold change values of 17.47, 13.05, 12.67, and 12.11. The top four downregulated proteins were C-reactive protein (CRP), Tubulin alpha-1A (TUBA1A), fibronectin, and LPA with fold change values of −1.73, −1.73, −1.52, and −1.48, respectively.

In addition, a total of 81 proteins were differentially expressed between SANFH-TCM and SANFH ([Table 4](#tab4){ref-type="table"}), including significantly 44 upregulated proteins (\>1.21-fold, *P* \< 0.05) and 37 significantly downregulated proteins (\<0.83-fold, *P* \< 0.05). The top four upregulated proteins in SANFH-TCM compared to SANFH were ABCB9, IQ, and AAA domain-containing protein 1 (IQCA1), fibrinogen alpha, and fibrinogen beta, which showed the fold change values of 21.82, 13.86, 13.66, and 13.64, respectively. The top four downregulated proteins were serum amyloid A-2 (SAA2), Ig lambda, CRP, and collagen alpha-1 with fold change values of −2.36, −2.26, −2.24, and −2.04, respectively.

3.3. Biomarkers Prediction and Validation {#sec3.3}
-----------------------------------------

MRM was performed to verify the results obtained from iTRAQ proteomics ([Figure 1](#fig1){ref-type="fig"}). The upregulation of fibrinogen alpha, fibrinogen beta, and fibrinogen gamma and apolipoprotein A (LPA) and apolipoprotein D (LPD) in SANFH-TCM versus healthy controls and SANFH-TCM versus SANFH was confirmed by MRM, respectively (*P* \< 0.05). Meanwhile, MRM also verified the decreased expression of fibronectin and CRP in SANFH-TCM versus healthy controls and SANFH-TCM versus SANFH identified by iTRAQ, respectively (*P* \< 0.05) ([Table 5](#tab5){ref-type="table"}). In SANFH versus healthy controls, CRP and LPA were confirmed to upregulate, and LPD and apolipoprotein E (LPE) were confirmed to downregulate. Using MRM, fibrinogen alpha, fibrinogen beta, and fibrinogen gamma were significantly increased in SANFH compared with healthy controls. However, iTRAQ did not detect significant changes in the expression of fibrinogen alpha, fibrinogen beta, and fibrinogen gamma between SANFH and healthy controls. Although some difference existed between iTRAQ and MRM, all these data added confidence to the results obtained from iTRAQ.

3.4. Go Analysis of Differentially Expressed Proteins {#sec3.4}
-----------------------------------------------------

The differentially expressed proteins (SANFH versus healthy controls, SANFH-TCM versus healthy controls, and SANFH-TCM versus SANFH) were classified by Gene Ontology (GO) based on their cellular component, molecular function, and biological process.

For SANFH versus healthy controls ([Figure 2](#fig2){ref-type="fig"}), the top five significantly enriched GO terms concerning biological process were mainly associated with purine ribonucleotide biosynthetic process, nucleoside phosphate biosynthetic process, negative regulation of endothelial cell proliferation, mitochondrial transport and immune response-regulating signaling pathway, and cellular component, in which the top listed five GO terms were proton-transporting two-sector ATPase complex, catalytic domain, proton-transporting two-sector ATPase complex, proton-transporting ATP synthase complex, pigment granule, and organelle inner membrane. With respect to molecular function, transmembrane transporter activity, substrate-specific transmembrane transporter activity, primary active transmembrane transporter activity, p-p-bond-hydrolysis-driven transmembrane transporter activity, and monovalent inorganic cation transmembrane transporter activity were the top five GO terms.

For SANFH-TCM versus healthy controls ([Figure 3](#fig3){ref-type="fig"}), transport, response to organic substance, response to chemical, response to calcium ion, and regulation of triglyceride metabolic process were the top five GO terms concerning biological process; vesicle lumen, site of polarized growth, secretory granule lumen, secretory granule, and platelet alpha granule lumen were the top five GO terms concerning cellular component; and sulfur compound binding, small molecule binding, serine-type endopeptidase inhibitor activity, quaternary ammonium group binding, and peptidase regulator activity were the top five GO terms concerning molecular function.

For SANFH-TCM versus SANFH ([Figure 4](#fig4){ref-type="fig"}), most enriched GO terms were response to metal ion, response to inorganic substance, response to calcium ion, regulation of lipoprotein oxidation, and protein polymerization in biological process, site of polarized growth, secretory granule lumen, secretory granule, ribosome, and platelet alpha granule in cellular component, and sulfur compound binding, serine-type endopeptidase inhibitor activity, scavenger receptor activity, ribonuclease activity, and ribonuclease A activity in molecular function.

3.5. Pathway Enrichment Analysis of Differentially Expressed Proteins {#sec3.5}
---------------------------------------------------------------------

The differentially expressed proteins (SANFH versus healthy controls, SANFH-TCM versus healthy controls, and SANFH-TCM versus SANFH) were mapped to the reference pathways in KEGG database to identify significantly enriched metabolic pathways or signal transduction pathways. In total, 47, 58, and 20 significantly enriched pathways were obtained in SANFH versus healthy controls ([Table 6](#tab6){ref-type="table"}), SANFH-TCM versus healthy controls ([Table 7](#tab7){ref-type="table"}), and SANFH-TCM versus SANFH ([Table 8](#tab8){ref-type="table"}) (*P* \< 0.05), respectively. The top listed five pathways were Alzheimer\'s disease, salivary secretion, Huntington\'s disease, Parkinson\'s disease, and oxidative phosphorylation in SANFH versus healthy controls ([Table 6](#tab6){ref-type="table"}); mineral absorption, PPAR signaling pathway, chemokine signaling pathway, adrenergic signaling in cardiomyocytes, and neurotrophin signaling pathway in SANFH-TCM versus healthy controls ([Table 7](#tab7){ref-type="table"}); and chemokine signaling pathway, platelet activation, cytokine-cytokine receptor interaction, glycosylphosphatidylinositol- (GPI-) anchor biosynthesis, and beta-alanine metabolism in SANFH-TCM versus SANFH ([Table 8](#tab8){ref-type="table"}) (*P* \< 0.03), respectively. The predicted biomarker LPE was involved in the enriched pathway of Alzheimer\'s disease in both SANFH versus healthy and SANFH-TCM versus healthy controls. In SANFH-TCM versus healthy controls, LPA was involved in the enriched pathway of PPAR signaling pathway; fibronectin was involved in the enriched pathway of pathways in cancer, small-cell lung cancer, and bacterial invasion of epithelial cells. Fibrinogen alpha, fibrinogen beta, and fibrinogen gamma were involved in the enriched pathway of platelet activation in both SANFH-TCM versus healthy controls and SANFH-TCM versus SANFH. In SANFH-TCM versus SANFH, fibronectin was involved in the enriched pathway of regulation of actin cytoskeleton, and fibrinogen gamma was also involved in the enriched pathway of*Staphylococcus aureus* infection.

4. Discussion {#sec4}
=============

This is the first study to reveal proteins associated with steroid-induced avascular necrosis of the femoral head with or without Traditional Chinese Medicine treatment on the proteome level. MRM was used to add confidence to the results obtained by iTRAQ and was attempted for validating 8 proteins (fibrinogen alpha, fibrinogen beta, fibrinogen gamma, fibronectin, C-reactive protein, apolipoprotein A, apolipoprotein D, and apolipoprotein E).

Currently, the pathogenesis theories on femoral head necrosis mainly include \[[@B27], [@B28]\]: theory of osteoporosis; theory of vascular wall damage or compression and theory of blood lipid disorder \[[@B29]\]; theory of high intraosseous pressure; theory of intravascular coagulation; theory of secondary collision; and so forth \[[@B30]\]. Secondary collision theory \[[@B31]\] considers that osteonecrosis of the femoral head is multifactor disease and it is related to genetic susceptibility factor and exposure to specific risk factors. The occurrence of femoral head necrosis is the collusion result of posterior acquired factors and genetic predisposing factor. Clinical studies also indicate that not all patients that had taken high dose hormone for a long time will suffer from femoral head necrosis and only 10% of patients will be attacked by femoral head necrosis. Though there are many clinical and basis studies about femoral head avascular necrosis, its specific pathophysiological mechanism is still not determined \[[@B10], [@B14]\]. The beginning of proteomic technology applying in femoral head necrosis is relatively late and there are rare reports. The proteomics study of femoral head necrosis will be helpful to explain the pathological physiology mechanism of femoral head necrosis.

By using meprednisone to induce chicken femoral head necrosis, Li et al. \[[@B32]\] found that there are adipose tissue proliferation and new bone formation through the histological examination; by two-dimensional electrophoresis, 13 protein expression differences were found. Among them, 9 kinds of proteins were downregulated 3 times after hormone treatment, which were serum amyloid P-component precursor, zinc finger protein 28, endothelial zinc finger protein 71, T-box transcription factor 3, cyclin-dependent kinase inhibitor 1, myosin 1D, dimethylaniline monooxygenase, and two kinds of unknown proteins. However, the animal species were different, the cases in the clinical study were few, and the pathogenesis was different, so they lacked comparability and the study results were also different, without representativeness, so they were not sufficient to explain the pathogenesis of femoral head necrosis.

Considering the sampling of bone tissue is an invasive operation, which will bring regional trauma for patients increasing their suffering, the sampling of serum is easier and is also easy for patients to accept. There are few studies on femoral head necrosis. Researchers \[[@B3], [@B33]\] conducted serum proteomics study on 11 patients with drinking, hormone treatment, or specific femoral head necrosis (3 female and 8 male) and they found 8 protein differential points. Comparing with the serum of healthy volunteers, the serum of patients with femoral head had higher kininogen 1 variant, complement factor C3 precursor, and complement factor H. Besides, patients with femoral head necrosis had significant lower apolipoprotein A-IV precursor, antithrombin III chain B, and gelsolin isoform *α* precursor.

In the present study, we further suggested that the serum amyloid A-2 (SAA2), Ig lambda, sodium/potassium-transporting ATPase subunit alpha-3 (ATP1A3), calcium-binding mitochondrial carrier protein Aralar1 (SLC25A12), properdin, KRT9, LPA, TPM4, ABCB9, fibrinogen alpha, fibrinogen gamma, fibrinogen beta, CRP, TUBA1A, fibronectin, IQCA1, SAA2, and collagen alpha-1 were potential serum marker by iTRAQ and further confirmed the changes of fibrinogen alpha, fibrinogen beta, fibrinogen gamma, fibronectin, C-reactive protein, apolipoprotein A, apolipoprotein D, and apolipoprotein E. The predicted biomarker LPE was involved in the enriched pathway of Alzheimer\'s disease; LPA was involved in the enriched pathway of PPAR signaling pathway; fibronectin was involved in the enriched pathway of pathways in cancer, small-cell lung cancer, and bacterial invasion of epithelial cells; fibrinogen alpha, fibrinogen beta, and fibrinogen gamma were involved in the enriched pathway of platelet activation; fibronectin was involved in the enriched pathway of regulation of actin cytoskeleton, and fibrinogen gamma was also involved in the enriched pathway of*Staphylococcus aureus* infection. Consistently, it has demonstrated that apolipoprotein A1 is potential risk for femoral head necrosis \[[@B34]--[@B36]\]. Fibronectin related to extracellular matrix integrity and adhesion is also an identified serum marker for broiler chickens with femoral head necrosis \[[@B35]\]. Fibrinogen beta was candidate biomarker of infection and inflammation \[[@B37]\] and femoral head necrosis \[[@B35]\]. CRP is an acute-phase protein, negatively correlated with adiponectin level in osteonecrosis of the femoral head \[[@B38]\].

In conclusion, our results identified 74 differentially expressed proteins between SANTH-TCM and healthy controls, 62 proteins between SANFH and healthy controls, and 81 proteins between SANFH-TCM and SANFH. Those upregulated proteins including ABCB9, IQCA1, fibrinogen alpha, and fibrinogen beta and downregulated proteins including serum amyloid A-2 (SAA2), Ig lambda, CRP, and collagen alpha-1 are promising serum diagnosis markers of femoral head necrosis, and also the marker could be used for prognosis of femoral head necrosis after Traditional Chinese Medicine treatment. The key points of treating femoral head necrosis are early diagnosis, early treatment, and reserving femoral head of patients. Our findings on the screening of early serum diagnosis marker of femoral head necrosis are helpful for early intervention on patients with hormone risk factors and preventing femoral head necrosis.
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###### 

Demographic characteristics.

  In Total *n*                                  26
  --------------------------------------------- --------------
  Male, *n* (%)                                 11 (42.3)
  Age, yr, mean ± SD                            39.5 ± 5.3
  History of SONFH, months, median (min, max)   23.1 (6, 34)
  Primary disease, *n* (%)                       
  Systemic lupus erythematosus                  13 (50.0)
  Anaphylactoid purpura                         5 (19.2)
  Eczema                                        4 (15.4)
  Psoriasis                                     2 (7.7)
  Thrombocytopenic purpura                      1 (3.8)
  Fever of unknown origin                       1 (3.8)

###### 

Differentially expressed protein between SANFH and healthy controls.

  Accession                 Description                                             *P* value       Ratio (mean)
  ------------------------- ------------------------------------------------------- --------------- --------------
  *Upregulated protein*                                                                             
  P0DJI9                    Serum amyloid A-2 protein                               0.0000233       4.57402273
  P01714                    Ig lambda chain V-III region SH                         0.000116405     2.64233333
  P13637                    Sodium/potassium-transporting ATPase subunit alpha-3    0.010160416     2.06683333
  O75746                    Calcium-binding mitochondrial carrier protein Aralar1   0.008612823     1.95325
  P01613                    Ig kappa chain V-I region Ni                            0.005619256     1.94854167
  P01743                    Ig heavy chain V-I region HG3                           0.00017147      1.93190909
  P01742                    Ig heavy chain V-I region EU                            1.61*E* − 18    1.8255
  P0DJI8                    Serum amyloid A-1 protein                               0.000000019     1.72607353
  P01857                    Ig gamma-1 chain C region                               2.12*E* − 208   1.71611466
  P01861                    Ig gamma-4 chain C region                               0.00000135      1.66788889
  P06889                    Ig lambda chain V-IV region MOL                         0.0000383       1.59966667
  P01860                    Ig gamma-3 chain C region                               6.59*E* − 46    1.59404098
  P02741                    C-reactive protein                                      6.38*E* − 146   1.58455808
  Q8NBJ4                    Golgi membrane protein 1                                0.000564362     1.4622
  P0C0L4                    Complement C4-A                                         1.33*E* − 10    1.45864286
  P12235                    ADP/ATP translocase 1                                   0.016291795     1.4491
  P06576                    ATP synthase subunit beta, mitochondrial                0.002154497     1.43466667
  P13645                    Keratin, type I cytoskeletal 10                         4.63*E* − 13    1.41348333
  P04433                    Ig kappa chain V-III region VG (Fragment)               0.000000732     1.412
  Q08380                    Galectin-3-binding protein                              3.33*E* − 45    1.38927444
  Q14624                    Inter-alpha-trypsin inhibitor heavy chain H4            6.37*E* − 87    1.37619099
  P22692                    Insulin-like growth factor-binding protein 4            0.025918263     1.362
  P01620                    Ig kappa chain V-III region SIE                         8.22*E* − 09    1.3591875
  P02452                    Collagen alpha-1(I) chain                               1.95*E* − 09    1.3503
  O75636                    Ficolin-3                                               2.26*E* − 53    1.341312
  P01717                    Ig lambda chain V-IV region Hil                         0.003213417     1.3341
  P14625                    Endoplasmin                                             0.00000523      1.3105
  P01621                    Ig kappa chain V-III region NG9 (Fragment)              0.000190716     1.2999
  P51884                    Lumican                                                 0.002279512     1.29618421
  P02747                    Complement C1q subcomponent subunit C                   1.85*E* − 11    1.290775
  P25705                    ATP synthase subunit alpha, mitochondrial               0.00000765      1.28091667
  P22792                    Carboxypeptidase N subunit 2                            7.1*E* − 09     1.27185227
  P09543                    2′,3′-Cyclic-nucleotide 3′-phosphodiesterase            0.034218978     1.2625
  P18428                    Lipopolysaccharide-binding protein                      2.71*E* − 47    1.25414706
  P01009                    Alpha-1-antitrypsin                                     6.68*E* − 34    1.21782482
  *Downregulated protein*                                                                           
  P01781                    Ig heavy chain V-III region GAL                         0.00000597      0.82966667
  O43852                    Calumenin                                               0.000374747     0.82916667
  Q9UK55                    Protein Z-dependent protease inhibitor                  2.62*E* − 11    0.82908108
  O43866                    CD5 antigen-like                                        1.19*E* − 23    0.82744578
  Q04756                    Hepatocyte growth factor activator                      0.000530289     0.821
  P63104                    14-3-3 protein zeta/delta                               0.009022339     0.8194
  Q68CQ4                    Digestive organ expansion factor homolog                0.000458581     0.81775
  P68366                    Tubulin alpha-4A chain                                  0.003314178     0.8143
  P04211                    Ig lambda chain V region 4A                             0.021633191     0.812
  Q6Q788                    Apolipoprotein A-V                                      0.000000051     0.8107381
  P59665                    Neutrophil defensin 1                                   0.011081692     0.7993
  P05164                    Myeloperoxidase                                         0.001604817     0.7984
  P02649                    Apolipoprotein E                                        5.01*E* − 267   0.7911827
  P04070                    Vitamin K-dependent protein C                           1.41*E* − 22    0.78128922
  Q13103                    Secreted phosphoprotein 24                              9.56*E* − 09    0.76858333
  P02749                    beta-2-Glycoprotein 1                                   0.015081278     0.7567
  P01591                    Immunoglobulin J chain                                  2.38*E* − 17    0.75358772
  P36980                    Complement factor H-related protein 2                   0.000968476     0.75325
  P04220                    Ig mu heavy chain disease protein                       0.047631742     0.74433333
  P01871                    Ig mu chain C region                                    2.52*E* − 147   0.72098342
  Q71U36                    Tubulin alpha-1A chain                                  0.005388449     0.716
  P62158                    Calmodulin                                              0.002744078     0.63166667
  P67936                    Tropomyosin alpha-4 chain                               0.002042575     0.62
  P08519                    Apolipoprotein(a)                                       1.36*E* − 09    0.606
  P35527                    Keratin, type I cytoskeletal 9                          1.13*E* − 09    0.57923077
  P27918                    Properdin                                               2.97*E* − 34    0.57908333

###### 

Differentially expressed protein between SANFH-TCM and healthy controls.

  Accession                 Description                                            *P* value      Ratio (mean)
  ------------------------- ------------------------------------------------------ -------------- --------------
  *Upregulated protein*                                                                           
  Q9NP78                    ATP-binding cassette subfamily B member 9              8.47*E* − 09   17.47338
  P02671                    Fibrinogen alpha chain                                 0              13.049
  P02679                    Fibrinogen gamma chain                                 0              12.66544
  P02675                    Fibrinogen beta chain                                  0              12.11164
  Q86XH1                    IQ and AAA domain-containing protein 1                 0.000199       8.9745
  P01019                    Angiotensinogen                                        9.49*E* − 09   2.256
  Q68CQ4                    Digestive organ expansion factor homolog               0.000267       1.882
  P03950                    Angiogenin                                             4.8*E* − 10    1.7776
  P13637                    Sodium/potassium-transporting ATPase subunit alpha-3   0.017893       1.742833
  Q8WXD2                    Secretogranin-3                                        1.34*E* − 07   1.71675
  P06396                    Gelsolin                                               3.3*E* − 46    1.659898
  Q8NBJ4                    Golgi membrane protein 1                               7.61*E* − 08   1.6227
  Q96KN2                    Beta-Ala-His dipeptidase                               1.18*E* − 06   1.588538
  P02775                    Platelet basic protein                                 1.22*E* − 17   1.544688
  P06727                    Apolipoprotein A-IV                                    0              1.529316
  P01023                    Alpha-2-macroglobulin                                  1.85*E* − 68   1.506488
  Q14624                    Inter-alpha-trypsin inhibitor heavy chain H4           4.2*E* − 152   1.503549
  P02776                    Platelet factor 4                                      1.49*E* − 56   1.487591
  Q7Z2Y8                    Interferon-induced very large GTPase 1                 0.047372       1.4735
  P29122                    Proprotein convertase subtilisin/kexin type 6          0.002827       1.47275
  P05154                    Plasma serine protease inhibitor                       1.09*E* − 06   1.446654
  P14618                    Pyruvate kinase PKM                                    0.005908       1.444167
  P06889                    Ig lambda chain V-IV region MOL                        9.86*E* − 05   1.4295
  P01857                    Ig gamma-1 chain C region                              4*E* − 180     1.427066
  P22792                    Carboxypeptidase N subunit 2                           3.39*E* − 15   1.348591
  P01742                    Ig heavy chain V-I region EU                           3.44*E* − 19   1.343614
  P05090                    Apolipoprotein D                                       1.43*E* − 66   1.330211
  P51884                    Lumican                                                6.82*E* − 07   1.323868
  P01613                    Ig kappa chain V-I region Ni                           6.17*E* − 05   1.319958
  P01860                    Ig gamma-3 chain C region                              4.37*E* − 19   1.318262
  P14625                    Endoplasmin                                            0.000738       1.3125
  Q04756                    Hepatocyte growth factor activator                     4.34*E* − 05   1.312333
  P80108                    Phosphatidylinositol-glycan-specific phospholipase D   6.28*E* − 16   1.309714
  P02787                    Serotransferrin                                        0.03443        1.2721
  P00450                    Ceruloplasmin                                          1.43*E* − 27   1.269935
  P10720                    Platelet factor 4 variant                              1.65*E* − 05   1.255714
  P80748                    Ig lambda chain V-III region LOI                       0.003          1.24625
  P01009                    Alpha-1-antitrypsin                                    6.2*E* − 51    1.245105
  Q9NP79                    Coagulation factor XII                                 0.001987       1.24225
  P02671                    Retinoic acid receptor responder protein 2             0.008513       1.234583
  P02679                    Ig kappa chain V-II region TEW                         0.024594       1.226038
  P02675                    Kallistatin                                            0.016269       1.223857
  Q86XH2                    Complement C1q subcomponent subunit A                  8.72*E* − 05   1.222116
  P01020                    FERM and PDZ domain-containing protein 1               2.36*E* − 06   1.212885
  Q68CQ5                    Retinol-binding protein 4                              4.81*E* − 08   1.2112
  *Downregulated protein*                                                                         
  Q02818                    Nucleobindin-1                                         0.002012       0.8295
  Q9UK55                    Protein Z-dependent protease inhibitor                 2.62*E* − 11   0.829081
  P02656                    Apolipoprotein C-III                                   3.32*E* − 34   0.823015
  P62258                    14-3-3 protein epsilon                                 0.04376        0.81975
  P01877                    Ig alpha-2 chain C region                              0.024488       0.817692
  Q6Q788                    Apolipoprotein A-V                                     5.25*E* − 08   0.81769
  P36980                    Complement factor H-related protein 2                  0.001599       0.815458
  P35542                    Serum amyloid A-4 protein                              2.65*E* − 29   0.813253
  P01620                    Ig kappa chain V-III region SIE                        1.42*E* − 05   0.800375
  O14818                    Proteasome subunit alpha type-7                        0.024316       0.794833
  P18428                    Lipopolysaccharide-binding protein                     4.26*E* − 75   0.789371
  P04438                    Ig heavy chain V-II region SESS                        0.044412       0.78775
  P49721                    Proteasome subunit beta type-2                         0.026571       0.7765
  P04196                    Histidine-rich glycoprotein                            6.01*E* − 28   0.775008
  P02649                    Apolipoprotein E                                       0              0.75853
  Q86UD1                    Out at first protein homolog                           7.29*E* − 08   0.755267
  P04211                    Ig lambda chain V region 4A                            1.19*E* − 05   0.751667
  P0DJI9                    Serum amyloid A-2 protein                              7.71*E* − 05   0.744667
  P67936                    Tropomyosin alpha-4 chain                              0.0005         0.74375
  Q8NDV3                    Structural maintenance of chromosomes protein 1B       0.000726       0.741833
  P62158                    Calmodulin                                             0.005327       0.733667
  Q16610                    Extracellular matrix protein 1                         5.58*E* − 10   0.731882
  Q92954                    Proteoglycan 4                                         7.15*E* − 12   0.728857
  P59665                    Neutrophil defensin 1                                  0.000151       0.7177
  P20742                    Pregnancy zone protein                                 4.88*E* − 71   0.696948
  P02741                    C-reactive protein                                     2.7*E* − 173   0.677154
  Q71U36                    Tubulin alpha-1A chain                                 0.000833       0.657333
  P02751                    Fibronectin                                            0              0.635439
  P08519                    Apolipoprotein(a)                                      7.96*E* − 09   0.56335

###### 

Differentially expressed protein between SANFH-TCM and SANFH.

  Accession                 Description                                            *P* value       Ratio (mean)
  ------------------------- ------------------------------------------------------ --------------- --------------
  *Upregulated protein*                                                                            
  Q9NP78                    ATP-binding cassette sub-family B member 9             7.38*E* − 10    21.82029412
  Q86XH1                    IQ and AAA domain-containing protein 1                 0.000343733     13.86725
  P02671                    Fibrinogen alpha chain                                 0               13.65918665
  P02675                    Fibrinogen beta chain                                  0               13.64325401
  P02679                    Fibrinogen gamma chain                                 0               13.23321597
  P01019                    Angiotensinogen                                        0.000000129     2.391730769
  Q68CQ4                    Digestive organ expansion factor homolog               0.0000351       2.26525
  P03950                    Angiogenin                                             0.00000196      2.0039
  P35527                    Keratin, type I cytoskeletal 9                         3.95*E* − 11    1.928576923
  Q8WXD2                    Secretogranin-3                                        0.000728124     1.91025
  P27918                    Properdin                                              1.39*E* − 40    1.763869048
  P14618                    Pyruvate kinase PKM                                    0.002960903     1.632333333
  P05154                    Plasma serine protease inhibitor                       2.03*E* − 12    1.607923077
  Q04756                    Hepatocyte growth factor activator                     2.81*E* − 08    1.590333333
  P02775                    Platelet basic protein                                 2.34*E* − 18    1.56775
  P02776                    Platelet factor 4                                      3.43*E* − 84    1.559232955
  P02749                    Beta-2-glycoprotein 1                                  0.0000322       1.548
  Q96KN2                    Beta-Ala-His dipeptidase                               0.0000169       1.533115385
  P01023                    Alpha-2-macroglobulin                                  1.1*E* − 62     1.519228916
  P06727                    Apolipoprotein A-IV                                    0               1.4910721
  P06396                    Gelsolin                                               7.08*E* − 33    1.485481481
  P01769                    Ig heavy chain V-III region GA                         0.009729195     1.45675
  P10720                    Platelet factor 4 variant                              0.000000465     1.450190476
  P05090                    Apolipoprotein D                                       5.92*E* − 70    1.385849624
  P19823                    Inter-alpha-trypsin inhibitor heavy chain H2           1.59*E* − 76    1.376936508
  P01871                    Ig mu chain C region                                   1.12*E* − 123   1.37344898
  P01616                    Ig kappa chain V-II region MIL                         0.004694041     1.35375
  P34096                    Ribonuclease 4                                         0.016807995     1.3485
  P29122                    Proprotein convertase subtilisin/kexin type 6          0.007174928     1.3275
  P80108                    Phosphatidylinositol-glycan-specific phospholipase D   1.54*E* − 12    1.320666667
  P55056                    Apolipoprotein C-IV                                    0.0000081       1.3169
  O95445                    Apolipoprotein M                                       0.00000275      1.314954545
  Q9UHG3                    Prenylcysteine oxidase 1                               0.00000266      1.305045455
  P08603                    Complement factor H                                    8.17*E* − 39    1.296578143
  P02787                    Serotransferrin                                        0.002337342     1.2947
  P05164                    Myeloperoxidase                                        0.020349711     1.282
  Q8WWA0                    Intelectin-1                                           0.0000227       1.2735
  P29622                    Kallistatin                                            0.0000069       1.267285714
  Q9NP79                    Immunoglobulin J chain                                 4.06*E* − 10    1.260973684
  Q86XH2                    CD5 antigen-like                                       3*E* − 31       1.248355422
  P02671                    Plasma kallikrein                                      6.95*E* − 08    1.236383333
  P02675                    Serum amyloid P-component                              1.03*E* − 24    1.236112319
  P02679                    Inter-alpha-trypsin inhibitor heavy chain H1           1.7*E* − 30     1.230389423
  P01019                    Alpha-actinin-4                                        0.045621384     1.23
  *Downregulated protein*                                                                          
  P04217                    Alpha-1B-glycoprotein                                  0.0000256       0.826346154
  P01613                    Ig kappa chain V-I region Ni                           0.010289928     0.825583333
  Q16610                    Extracellular matrix protein 1                         0.000000945     0.821529412
  Q92954                    Proteoglycan 4                                         1.05*E* − 09    0.8145
  Q02818                    Nucleobindin-1                                         0.000247875     0.813125
  P01742                    Ig heavy chain V-I region EU                           1.22*E* − 08    0.803428571
  P04434                    Ig kappa chain V-III region VH (Fragment)              0.030092513     0.802166667
  P55774                    C-C motif chemokine 18                                 0.003307656     0.79825
  Q9HDC9                    Adipocyte plasma membrane-associated protein           0.00000847      0.798083333
  P01011                    Alpha-1-antichymotrypsin                               7.56*E* − 13    0.796217391
  P01621                    Ig kappa chain V-III region NG9 (Fragment)             0.0000675       0.795
  P01717                    Ig lambda chain V-IV region Hil                        0.0000608       0.78905
  P04196                    Histidine-rich glycoprotein                            2.81*E* − 26    0.783991667
  P04433                    Ig kappa chain V-III region VG (Fragment)              0.00000651      0.783357143
  P35542                    Serum amyloid A-4 protein                              1.77*E* − 40    0.752563218
  P0DJI8                    Serum amyloid A-1 protein                              4.33*E* − 11    0.748036765
  P27824                    Calnexin                                               0.038086684     0.73825
  P00740                    Coagulation factor IX                                  6.16*E* − 23    0.733622222
  Q9UGM5                    Fetuin-B                                               0.00451302      0.721833333
  P0C0L4                    Complement C4-A                                        4.74*E* − 14    0.71725
  Q08380                    Galectin-3-binding protein                             9.69*E* − 59    0.713721805
  P04438                    Ig heavy chain V-II region SESS                        0.039314686     0.70425
  P20742                    Pregnancy zone protein                                 9.73*E* − 65    0.698695238
  P13645                    Keratin, type I cytoskeletal 10                        1.17*E* − 19    0.69635
  Q86UD1                    Out at first protein homolog                           3.02*E* − 09    0.694666667
  P02751                    Fibronectin                                            0               0.692870958
  P04208                    Ig lambda chain V-I region WAH                         0.000226793     0.6685
  P01861                    Ig gamma-4 chain C region                              2.47*E* − 08    0.655777778
  P18428                    Lipopolysaccharide-binding protein                     5.83*E* − 130   0.640994118
  P49721                    Proteasome subunit beta type-2                         0.019809794     0.6185
  P25789                    Proteasome subunit alpha type-4                        0.00601102      0.609
  P01743                    Ig heavy chain V-I region HG3                          0.0000275       0.607136364
  P01620                    Ig kappa chain V-III region SIE                        1.87*E* − 11    0.5894375
  P02452                    Collagen alpha-1(I) chain                              0.000916641     0.4901
  P02741                    C-reactive protein                                     1.19*E* − 243   0.445641414
  P01714                    Ig lambda chain V-III region SH                        1.91*E* − 09    0.442666667
  P0DJI9                    Serum amyloid A-2 protein                              1.16*E* − 08    0.424595238

###### 

MRM was performed to verify the results obtained from iTRAQ proteomics.

  Accession number   Description          Relative protein abundance (MRM)   Relative protein abundance (iTRAQ)                             
  ------------------ -------------------- ---------------------------------- ------------------------------------ --------- ------- ------- -------
  P02671             Fibrinogen alpha     1.8493                             62.3799                              33.7321   0.95    7.502   7.849
  P02675             Fibrinogen beta      3.2104                             143.2262                             44.6126   0.936   5.8     6.161
  P02679             Fibrinogen gamma     1.7341                             79.1554                              45.6467   0.953   6.721   6.766
  P02751             Fibronectin          0.8527                             0.3081                               0.3614    0.999   0.568   0.571
  P02741             C-reactive protein   2.2723                             0.522                                0.2297    1.559   0.658   0.412
  P06727             Apolipoprotein A     1.2723                             1.8632                               1.4644    1.06    1.532   1.45
  P05090             Apolipoprotein D     0.9796                             1.4369                               1.4668    0.932   1.302   1.341
  P02649             Apolipoprotein E     0.6693                             0.6865                               1.0257    0.759   0.713   0.934

###### 

Differently enriched pathways were obtained in SANFH versus healthy controls.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pathway_acc   Pathway_Name                                       *P* value   Protein in Background   Protein in Diff Exp   Protein list
  ------------- -------------------------------------------------- ----------- ----------------------- --------------------- ----------------------------------
  hsa05010      Alzheimer\'s disease                               0.015362    7                       4                     P25705, *P02649*, P62158, P06576

  hsa04970      Salivary secretion                                 0.032411    5                       3                     P62158, P04220, P13637,

  hsa05016      Huntington\'s disease                              0.057318    6                       3                     P25705, P12235, P06576,

  hsa05012      Parkinson\'s disease                               0.057318    6                       3                     P25705, P12235, P06576,

  hsa00190      Oxidative phosphorylation                          0.070274    3                       2                     P25705, P06576,

  hsa04261      Adrenergic signaling in cardiomyocytes             0.088785    7                       3                     P67936, P62158, P13637,

  hsa04915      Estrogen signaling pathway                         0.125873    4                       2                     P62158, P14625,

  hsa04020      Calcium signaling pathway                          0.125873    4                       2                     P12235, P62158,

  hsa04974      Protein digestion and absorption                   0.125873    4                       2                     P13637, P02452,

  hsa04260      Cardiac muscle contraction                         0.125873    4                       2                     P67936, P13637,

  hsa04961      Endocrine and other \                              0.162907    1                       1                     P13637,
                factor-regulated calcium reabsorption                                                                        

  hsa04964      Proximal tubule bicarbonate reclamation            0.162907    1                       1                     P13637,

  hsa04960      Aldosterone-regulated sodium reabsorption          0.162907    1                       1                     P13637,

  hsa04070      Phosphatidylinositol signaling system              0.162907    1                       1                     P62158,

  hsa04744      Phototransduction                                  0.162907    1                       1                     P62158,

  hsa04976      Bile secretion                                     0.162907    1                       1                     P13637,

  hsa05130      Pathogenic Escherichia coli infection              0.167478    9                       3                     Q71U36, P63104, P68366,

  hsa04918      Thyroid hormone synthesis                          0.188181    5                       2                     P14625, P13637,

  hsa04971      Gastric acid secretion                             0.188181    5                       2                     P62158, P13637,

  hsa04540      Gap junction                                       0.253612    6                       2                     Q71U36, P68366,

  hsa04972      Pancreatic secretion                               0.299618    2                       1                     P13637,

  hsa04720      Long-term potentiation                             0.299618    2                       1                     P62158,

  hsa04911      Insulin secretion                                  0.299618    2                       1                     P13637,

  hsa05214      Glioma                                             0.299618    2                       1                     P62158,

  hsa04978      Mineral absorption                                 0.299618    2                       1                     P13637,

  hsa04973      Carbohydrate digestion and absorption              0.299618    2                       1                     P13637,

  hsa04014      Ras signaling pathway                              0.299618    2                       1                     P62158,

  hsa04270      Vascular smooth muscle contraction                 0.299618    2                       1                     P62158,

  hsa04910      Insulin signaling pathway                          0.299618    2                       1                     P62158,

  hsa05031      Amphetamine addiction                              0.299618    2                       1                     P62158,

  hsa04750      Inflammatory mediator regulation of TRP channels   0.299618    2                       1                     P62158,

  hsa04912      GnRH signaling pathway                             0.299618    2                       1                     P62158,

  hsa05152      Tuberculosis                                       0.319543    7                       2                     P18428, P62158,

  hsa05150      Staphylococcus aureus infection                    0.334256    18                      4                     P00751, P0C0L4, P13645, P02747

  hsa04120      Ubiquitin mediated proteolysis                     0.357215    13                      3                     P01742, P01781, P01743,

  hsa04114      Oocyte meiosis                                     0.3841      8                       2                     P63104, P62158,

  hsa04919      Thyroid hormone signaling pathway                  0.41429     3                       1                     P13637,

  hsa04916      Melanogenesis                                      0.41429     3                       1                     P62158,

  hsa04064      NF-kappa B signaling pathway                       0.41429     3                       1                     P18428,

  hsa04728      Dopaminergic synapse                               0.41429     3                       1                     P62158,

  hsa04621      NOD-like receptor signaling pathway                0.41429     3                       1                     P14625,

  hsa05215      Prostate cancer                                    0.41429     3                       1                     P14625,

  hsa04740      Olfactory transduction                             0.41429     3                       1                     P62158,

  hsa04620      Toll-like receptor signaling pathway               0.41429     3                       1                     P18428,

  hsa04713      Circadian entrainment                              0.41429     3                       1                     P62158,

  hsa03320      PPAR signaling pathway                             0.445992    9                       2                     P08519, Q6Q788,

  hsa05133      Pertussis                                          0.45325     15                      3                     P0C0L4, P62158, P02747,
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note*. Italic font indicated the candidate protein.

###### 

Differently enriched pathways were obtained in SANFH-TCM versus healthy controls.

  Pathway_acc   Pathway_Name                                                *P* value   Protein in background   Proteins in Diff Exp   Protein list
  ------------- ----------------------------------------------------------- ----------- ----------------------- ---------------------- -----------------------------------
  hsa04978      Mineral absorption                                          0.034949    2                       2                      P02787, P13637,
  hsa03320      PPAR signaling pathway                                      0.068345    9                       4                      P02656, P08519, Q6Q788, *P06727*,
  hsa04062      Chemokine signaling pathway                                 0.083136    6                       3                      P10720, P02776, P02775,
  hsa04261      Adrenergic signaling in cardiomyocytes                      0.126188    7                       3                      P62158, P67936, P13637,
  hsa04722      Neurotrophin signaling pathway                              0.161789    4                       2                      P62158, P62258,
  hsa04915      Estrogen signaling pathway                                  0.161789    4                       2                      P62158, P14625,
  hsa04260      Cardiac muscle contraction                                  0.161789    4                       2                      P67936, P13637,
  hsa04114      Oocyte meiosis                                              0.17539     8                       3                      P62158, P62258, Q8NDV3,
  hsa00410      beta-Alanine metabolism                                     0.18797     1                       1                      Q96KN2,
  hsa04964      Proximal tubule bicarbonate reclamation                     0.18797     1                       1                      P13637,
  hsa00340      Histidine metabolism                                        0.18797     1                       1                      Q96KN2,
  hsa04070      Phosphatidylinositol signaling system                       0.18797     1                       1                      P62158,
  hsa04961      Endocrine and other factor-regulated calcium reabsorption   0.18797     1                       1                      P13637,
  hsa04976      Bile secretion                                              0.18797     1                       1                      P13637,
  hsa00860      Porphyrin and chlorophyll metabolism                        0.18797     1                       1                      P00450,
  hsa00563      Glycosylphosphatidylinositol (GPI)-anchor biosynthesis      0.18797     1                       1                      P80108,
  hsa04960      Aldosterone-regulated sodium reabsorption                   0.18797     1                       1                      P13637,
  hsa00230      Purine metabolism                                           0.18797     1                       1                      P14618,
  hsa04666      Fc gamma R-mediated phagocytosis                            0.18797     1                       1                      P06396,
                                                                                                                                       
  hsa02010      ABC transporters                                            0.18797     1                       1                      Q9NP78,
  hsa04744      Phototransduction                                           0.18797     1                       1                      P62158,
  hsa04611      Platelet activation                                         0.228912    9                       3                      *P02675*, *P02679*, *P02671*,
  hsa04060      Cytokine-cytokine receptor interaction                      0.228912    9                       3                      P10720, P02776, P02775,
  hsa04918      Thyroid hormone synthesis                                   0.23765     5                       2                      P14625, P13637,
  hsa04971      Gastric acid secretion                                      0.23765     5                       2                      P62158, P13637,
  hsa04970      Salivary secretion                                          0.23765     5                       2                      P62158, P13637,
  hsa05200      Pathways in cancer                                          0.314907    6                       2                      *P02751*, P14625,
  hsa04910      Insulin signaling pathway                                   0.340991    2                       1                      P62158,
  hsa04912      GnRH signaling pathway                                      0.340991    2                       1                      P62158,
  hsa04911      Insulin secretion                                           0.340991    2                       1                      P13637,
  hsa04270      Vascular smooth muscle contraction                          0.340991    2                       1                      P62158,
  hsa05214      Glioma                                                      0.340991    2                       1                      P62158,
  hsa04014      Ras signaling pathway                                       0.340991    2                       1                      P62158,
  hsa04614      Renin-angiotensin system                                    0.340991    2                       1                      P01019,
  hsa05222      Small cell lung cancer                                      0.340991    2                       1                      *P02751*,
  hsa05031      Amphetamine addiction                                       0.340991    2                       1                      P62158,
  hsa04750      Inflammatory mediator regulation of TRP channels            0.340991    2                       1                      P62158,
  hsa04720      Long-term potentiation                                      0.340991    2                       1                      P62158,
  hsa04973      Carbohydrate digestion and absorption                       0.340991    2                       1                      P13637,
  hsa04972      Pancreatic secretion                                        0.340991    2                       1                      P13637,
  hsa05203      Viral carcinogenesis                                        0.342177    11                      3                      P14618, P06396, P62258,
  hsa05152      Tuberculosis                                                0.390394    7                       2                      P18428, P62158,
  hsa04110      Cell cycle                                                  0.390394    7                       2                      P62258, Q8NDV3,
  hsa03050      Proteasome                                                  0.390394    7                       2                      P49721, O14818,
  hsa05010      Alzheimer\'s disease                                        0.390394    7                       2                      P62158, *P02649*,
                                                                                                                                       
  hsa04740      Olfactory transduction                                      0.465489    3                       1                      P62158,
  hsa04713      Circadian entrainment                                       0.465489    3                       1                      P62158,
  hsa04728      Dopaminergic synapse                                        0.465489    3                       1                      P62158,
  hsa04064      NF-kappa B signaling pathway                                0.465489    3                       1                      P18428,
  hsa04930      Type II diabetes mellitus                                   0.465489    3                       1                      P14618,
  hsa04620      Toll-like receptor signaling pathway                        0.465489    3                       1                      P18428,
  hsa04916      Melanogenesis                                               0.465489    3                       1                      P62158,
  hsa05100      Bacterial invasion of epithelial cells                      0.465489    3                       1                      *P02751*,
  hsa00620      Pyruvate metabolism                                         0.465489    3                       1                      P14618,
  hsa04919      Thyroid hormone signaling pathway                           0.465489    3                       1                      P13637,
  hsa04621      NOD-like receptor signaling pathway                         0.465489    3                       1                      P14625,
  hsa00330      Arginine and proline metabolism                             0.465489    3                       1                      Q96KN2,
  hsa05215      Prostate cancer                                             0.465489    3                       1                      P14625,

*Note*. Italic font indicated the candidate protein.

###### 

Differently enriched pathways were obtained in SANFH-TCM versus SANFH.

  Pathway_acc   Pathway_Name                                             *P* value    Protein in background   Proteins in Diff Exp   Protein list
  ------------- -------------------------------------------------------- ------------ ----------------------- ---------------------- -------------------------------------------
  hsa04062      Chemokine signaling pathway                              0.01871823   6                       4                      P10720, P55774, P02776, P02775,
  hsa04611      Platelet activation                                      0.0942118    9                       4                      *P02675*, *P02679*, *P02671*, P02452,
  hsa04060      Cytokine-cytokine receptor interaction                   0.0942118    9                       4                      P10720, P55774, P02776, P02775,
  hsa00563      Glycosylphosphatidylinositol (GPI)-anchor biosynthesis   0.2080201    1                       1                      P80108,
  hsa00410      beta-Alanine metabolism                                  0.2080201    1                       1                      Q96KN2,
  hsa02010      ABC transporters                                         0.2080201    1                       1                      Q9NP78,
  hsa04666      Fc gamma R-mediated phagocytosis                         0.2080201    1                       1                      P06396,
  hsa00900      Terpenoid backbone biosynthesis                          0.2080201    1                       1                      Q9UHG3,
  hsa00230      Purine metabolism                                        0.2080201    1                       1                      P14618,
  hsa00340      Histidine metabolism                                     0.2080201    1                       1                      Q96KN2,
  hsa04120      Ubiquitin mediated proteolysis                           0.2756015    13                      4                      P01742, P04438, P01769, P01743,
  hsa04810      Regulation of actin cytoskeleton                         0.2820364    9                       3                      *P02751*, O43707, P06396,
  hsa05150      Staphylococcus aureus infection                          0.3119404    18                      5                      P08603, P0C0L4, *P02679*, P06681, P13645,
  hsa05146      Amoebiasis                                               0.3460206    10                      3                      *P02751*, O43707, P02452,
  hsa05222      Small cell lung cancer                                   0.3731817    2                       1                      *P02751*,
  hsa04614      Renin-angiotensin system                                 0.3731817    2                       1                      P01019,
  hsa04978      Mineral absorption                                       0.3731817    2                       1                      P02787,
  hsa05412      Arrhythmogenic right ventricular cardiomyopathy (ARVC)   0.3731817    2                       1                      O43707,
  hsa05203      Viral carcinogenesis                                     0.4095525    11                      3                      P14618, O43707, P06396,
  hsa03050      Proteasome                                               0.4460931    7                       2                      P49721, P25789,

*Note*. Italic font indicated the candidate protein.

[^1]: Academic Editor: Yu-Chang Tyan
